Poolbeg Pharma patent portfolio significantly strengthened & expanded

Poolbeg Pharma plc (LON: POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2024.

Highlights, Business Update & Outlook

Cash balance of £10.1 million as at 30 June 2024, demonstrating continued prudent financial management
Independent research has confirmed a potential market opportunity of c.US$10 billion for POLB 001 as an orally delivered preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS)1
Robust data package in place for POLB 001 – efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo animal model, strengthening and facilitating the expansion of patent applications
US Patent Office granted the Company’s Immunomodulator II patent application covering a class of drugs, including POLB 001, to treat or prevent hypercytokinemia (cytokine storm) induced in any disease indication
Engagement continues with potential partners in relation to POLB 001
Exclusive 12-month option agreement signed for tPTX, a novel, topical, muco-adherent treatment for oral ulcers in patients suffering from Behçet’s Disease, with FDA Fast Track Designation, Orphan Drug Designation and potential 505(b)(2) approval pathway in the US
Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma Scientist discusses Oral GLP-1 receptors

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

POLB 001: A promising treatment for severe influenza

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Advancements shaping the future of drug discovery

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the

UCD leads in research collaboration and Poolbeg Pharma partnership

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for 2023. UCD, through its knowledge transfer

Cathal Friel on resilience, ambition and Ireland’s future

Business & Finance, established in 1964, is celebrating its 60th anniversary this year. To mark this milestone, the publication is conducting a series of Leadership interviews with influential figures shaping Ireland’s corporate landscape. One of these

AI’s impact on infectious disease drug development

Artificial intelligence (AI) represents a sophisticated form of machine learning capable of swiftly analysing extensive datasets, uncovering non-obvious patterns, and pinpointing novel disease targets along with potential drugs. AI is increasingly influencing drug development by identifying

Poolbeg Pharma’s innovative POLB001 demonstrates promising potential

Poolbeg Pharma plc, a forward-thinking biopharmaceutical company, has recently garnered attention for its groundbreaking work with POLB001, a novel therapeutic candidate showing significant promise in clinical research. As an emerging player in the pharmaceutical industry, Poolbeg

John McEvoy: The journey of an Irish unicorn

A unicorn is the title given to a start-up company that achieves a billion-dollar valuation. Newry-based John McEvoy was previously the Global General Counsel at a Dublin-based pharmaceutical company—a job he landed before he was 30—where

AI revolutionises drug discovery and pharmaceutical research

The future of drug discovery and pharmaceutical research is being reshaped by artificial intelligence (AI), heralding a new era of speed, efficiency, and precision. AI’s potential to accelerate drug development, from molecular prediction to optimised design